Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by C10H12N2on Apr 07, 2023 10:58am
92 Views
Post# 35384591

RE:RE:AP Loves The Thrill Of The Hunt Way More Than Kill-er Data

RE:RE:AP Loves The Thrill Of The Hunt Way More Than Kill-er Data
As predicted this morning at Arch's message board, you crawled out of a hole to defend your friend Riverfolk. You're a tight knit group of childish and predictablt "adults". You have consistently made up stuff as you go long. Just one tall tale after the next as anyone has time or cares to go back and debunk all your twisted rhetoric. My posts always have some factual merit. They're not have cocked with cockamamie conspiracy theories and straight up lies laced throughout. You Gaslight to no end. Surely, nobody here or at CEO.CA cares about that government funded handout Arch recently received to pay for ongoing operations. You rant just like your friend Riverfolk about all the success you would have experienced by now at Arch Biopartners. Now your new shtick is a 60% chance of success - smh. Those type of success rates seems like a phenomon only synonymous with Canadian upstarts. Such recklessnes would seem to be legally actionable. Irrespective of such reckless behaviour, your personal pitfalls remain on HD display. The grumpy old bear stays on the Attack Attack Attack. It's likely the most repetitive exercise you get beyond your Snore Score.
<< Previous
Bullboard Posts
Next >>